

RDP PHARMA

# PromptDegrader™ Platform

Proteasomal Oral Monovalent Protein Targeting

## Protein Degradation of Intrinsically Disordered Proteins (IDPs)

# Innovative Expansion to IDR beyond PROTACs and Glues




## Targeted protein degradation by PROTACs

A PROTAC simultaneously binds a **T**arget **o**f **I**nterest (**TOI**) and requires an E3 ubiquitin ligase complex, leading to ubiquitination and degradation of the TOI via the ubiquitin-proteosome system.




## Targeted protein degradation by PromptDegrader™

The PromptDegrader™ has a monovalent Mechanism of Action that binds to an **I**ntrinsically **D**isordered **R**egion (**IDR**) of the TOI and induces its degradation.

PromptDegrader™: Small molecules with a clear regulatory path complying to Lipinski rules, no Hook Effect, no competitive binding of PROTAC metabolites, improved PK / PD compared to PROTACs, orally available.

Created in https://BioRender.com

# Targeted Protein Degradation (TPD) Comparison Table

| PromptDegrader™ TPD Comparison | PromptDegrader™ | Molecular Glues | PROTACs |
|---|---|---|---|
| Targets IDRs of proteins | 🟢 | 🔴 | 🔴 |
| Freedom to operate / no IP “minefield” | 🟢 | 🟡 | 🔴 |
| Rational design<br>I. Activity screening<br>II. Biopharmaceutical & chemical optimization | 🟢 | 🟡 | 🔴 |
| Safety: no Hook Effect, reduced metabolization | 🟢 | 🟡 | 🔴 |
| Multi-modal: not reliant on single E3 ligase for degradation;<br>less risk of acquired and inherent resistance | 🟢 | 🟡 | 🔴 |

# Expanding Protein Degradation to IDR Proteins

- Targeted protein degradation of intrinsically disordered proteins (IDPs) with a rationally designed, small molecule discovery approach

  - POC *in vivo* for HPV **E7** and **c-MYC** degrader
    - *In vitro* high nm and µm activity translates into 10-20 mg/kg activity in rodents
    - Specificity: The E7 degrader is not active in c-MYC and *vice versa*
  - **β-catenin**, first physical compound hits chosen for further testing
  - **Second generation E7 degrader compounds**
    - Direct target engagement by NMR
    - Engagement with KOLs (e.g., Andrew Macdonald, University of Leeds)
  - Prompt method potentially drug > 100 IDR- human and viral protein targets
  - Common IDR sequences, induction of unfolded protein response, loss of function
  - Industrializing the platform
    - Contract with a third party for anti-inflammation IDR-protein target to be finalized
    - In discussion with investors and KOLs to target Hepatitis B IDR viral proteins


Created in https://BioRender.com

# Discovery Process PromptDegrader™

PRoteasomal Oral Monovalent Protein Targeting




- New small molecule pharmacophores, not reliant on *cereblon*, FTO
- Designed for proteins with IDRs

# Next Generation Targeted Protein Degradation

- IDR proteins are considered hard to drug*
- PromptDegraders™ can degrade IDR proteins
- Not only reliant on E3 modulation of ONE ligase, like PROTACs and Molecular Glues
- Avoid inherent and acquired resistance
- Vastly greater chemical space is available
- c-MYC data independently validated




* A.C. Pan. et al. "Molecular Basis of Small-Molecule Binding to α-Synuclein",
**"Drugging IDPs, however, has proven difficult due to their highly conformationally dynamic nature and the challenges associated with experimentally characterizing their conformational ensembles at atomic resolution. Because IDPs generally cannot be meaningfully represented by a single dominant conformation,
or even a small number of substantially populated conformations, they are generally not suitable targets for
conventional structure-based drug design methods, in which small molecules are designed to optimize interactions with a particular binding pocket in a folded protein. "**

J. Am. Chem. Soc. 2022, 144, 2501−2510. https://doi.org/10.1021/jacs.1c07591

# PromptDegrader™ Research Team

**Dr. Christian Kühne**
Chief Scientific Officer
25+ years of scientific innovation across multiple modalities and a first mover in the field of targeting intrinsically disordered regions for drugging difficult targets. Dr. Kuehne leads the PROMPT internal team and external collaborations.

**Dr. Markus Müllner**
Chief Technology Officer
15 years of biotech leadership in scientific innovation and business creation across multiple modalities and Targeted Protein Degradation.

## Biology Unit

Head:
**Dr. Florian Kellner**
Team:
14 scientists

## Chemistry Unit

Head:
**Dr. Antony Crisp**
Team:
8 scientists

## Computational Chemistry Unit

Interim Head:
**Prof. Diego Bustos**

Deputy Head:
**Dr. Paulina Pacak**


**Valdospan** (100% owned subsidiary) labs in Tulln, Austria

# RDP Pharma Overview and Leadership

## Susanne Oellrich – CEO

25+ years CRO experience in senior management functions including clinical operations, WW process and project and data management.

## Luis Bettinelli, PhD – COO

Global leadership experience spanning 25+ years in biotech, pharma and service providers and covering preclinical and clinical development.

## Michael Ahrweiler, PhD – CDO

Accomplished scientist and strategist with 25+ year record of development and deal-making. Deeply experienced across all phases of development.

## Wolfgang Meyer, PhD – Advisor

Internationally recognized expert in drug development with 35+ years of experience in big Pharma and Biotech.

## Company facts

- Swiss corporation, privately owned
- Headquarters: Romanshorn, Switzerland
- RDP Pharma has acquired two predecessor companies that developed the platform technology over the last decade

## PROMPT PIPELINE

| Product | Target | Indications | Discovery | Preclinical | Phase 1 |
|---|---|---|---|---|---|
| VS035 | E7 | Cancer: Head & Neck, Cervical | | | |
| TBD | MYC | Multiple | | | |
| TBD | Undisclosed | Multiple | | | |
| TBD | Undisclosed | Multiple | | | |

# CONTACT

**Dr. Michael Ahrweiler**
Founder, Chief Development Officer

michael.ahrweiler@rdp-pharma.com
Amriswilerstrasse 51
CH-8590 Romanshorn
Switzerland
Tel. +41 71 466 33 68
info@rdp-pharma.com
www.rdp-pharma.com